

Table 12: In all patients with vitiligo, what is the efficacy of a course of narrow-band UVB with a vitamin D analogue compared to narrow-band UVB with placebo in terms of condition progression, area reduction and QOL score? AV Anstey

Bibliographic citation	Study type	Ev lev	No of patients	Intervention	Comparison	Length follow-up	Outcomes measured and result	Additional comments
Leone G et al. 2006	randomised, open-label	1-	32	NB-UVB vs NB-UVB + tacalcitol	L vs R	6/12	Photos, arbitrary score. Significant difference between treated (ie TL01 + tacalcitol) and untreated sides (TL01 alone). P<0.05	Addition of tacalcitol to narrow-band UVB improved response
Kullavanijaya P. 2004	Open bilateral comparison study	2-	20	NB-UVB vs NB-UVB + calcipotriene	L vs R	Max 180 treatments	Arbitrary. 9/17 patients had a better improvement on the TL01 + calcipotriene-treated side than TL01 alone.	? better response on side treated with calcipotriene (not blinded)
Ada S. 2005;	Prospective, randomised, single-blinded, right-left comparison study	1-	20	NB-UVB vs NB-UVB + calcipotriol	L vs R	96 treatment sessions	Arbitrary score. "Cosmetically acceptable repigmentation in 11/20 (55%)	Narrow-band UVB was effective by itself, with no additional benefit from calcipotriol
Gokas EO. 2006	Open, not blinded or randomised	2-	24	NB-UVB vs NB-UVB + calcipotriol	L vs R	6/12	Arbitrary score. Open design. No blinding or randomisation. Within patient controls (ie L vs R)	Combination of NB-UVB with calcipotriol "potentiates" the efficacy
Kawalek AZ. 2004	Double-blind, placebo-controlled trial	1-	8	Excimer laser 3 X per week for maximum of 24 treatments or 10 weeks. 0.1% tacrolimus oint and placebo applied twice daily to randomly selected patches throughout the trial.	Arbitrary assessment of photographs	10 weeks	Arbitrary score. 50% of patches treated with combined Excimer + Tacrolimus achieved a 75% response, compared to 20% in the placebo group	"This combination therapy may represent a key advance in the treatment of vitiligo" !

Passeron T. 2004	Comparative, prospective, randomised, interindividual study	2-	14	Excimer laser 2 X per week for 24 sessions. Topical Tacrolimus to randomly selected lesions	Untreated control lesion was selected as comparator.		Assessment of direct and polarised light photographs taken before and after treatment. Repigmentation of 100% in combination group, 85% of Excimer monotherapy group and 0% in control group ($p < 0.002$)	"Tacrolimus + Excimer laser was superior to Excimer monotherapy"
Tjioe M. 2002	Randomised, controlled trial	1-	27	Narrow-band UVB + Vitamins B12 and Folate vs TL01 alone		12 months	Arbitrary	Co treatment with B12 and folate does not improve outcome. NB Data for the control arm could not be extracted.
Cherif F. 2003	Prospective, L vs R, open study	3	23	Calcipotriol + PUVA vs PUVA alone		15 weeks	Arbitrary. 69% showed "marked" improvement at 15 th treatment for combined treatment compared to 52% for PUVA alone ($p = 0.015$)	Treatment well tolerated. No adverse effects. Combination treatment was "effective, especially at initiating repigmentation"
Amen M. 2001	Open	3	4	PUVA + calcipotriol			Arbitrary	3 out of 4 showed a "good response"
Ermis O2001	RCT	1-	27	PUVA vs PUVA + calcipotriol	L vs R		Arbitrary Difference in response between placebo and calcipotriol-treated side was statistically significant ($p = 0.001$)	Earlier response and better overall response in Cal + PUVA group
Baysal V. 2003	Controlled trial	2-	22	PUVA vs PUVA + calcipotriol	L vs R		Arbitrary. Addition of calcipotriol did not lead to a significant increase in response rate compared to PUVA alone ($p = 0.980$)	No improved response with combined treatment
Parsad D. 1998	Randomised, double-blind, L vs R comparative study	1-	19	PUVA sol + calcipotriol vs PUVA sol monotherapy	L vs R		Arbitrary. 12 patients showed "complete improvement" on combination side compared to 6 patients on placebo-treated side (PUVA sol monotherapy)	"The combination of PUVA and calcipotriol os highly effective and works faster"
Schallreuter KU 2002	Prospective, randomised, placebo-	1-	59	Dead sea climatotherapy + pseudocatalase cream			30/39 had 50% or better response in pseudocatalase group. 0/10 in climatotherapy alone and 0/10 in	No adverse effects reported

